Abstract:BACKGROUND: It is estimated that about 30% of esophageal cancer (EC) patients are over 70 years old. Therefore, there is less evidence on the diagnosis and management of elderly EC patients. It is important to explore how elderly EC patients benefit from radical radiochemotherapy regimens, including the target area of radiotherapy (RT), radiation dose and fraction, and choice of chemotherapy drugs.AIM: To compare the efficacy of involved-field intensity-modulated RT (IF-IMRT) combined with S-1 vs RT alone in the treatment of elderly EC patients in terms of safety, short-term response, and survival.METHODS: Thirty-four EC patients aged > 70 years were prospectively enrolled between December 2017 and December 2019. Based on the random number table, they were divided into an IF-IMRT + S-1 group and an IF-IMRT alone group, with 17 patients in each group. All patients were treated with IF-IMRT at a dose of 50.4-56 Gy in 28-30 fractions (1.8-2 Gy/fraction, 5 fractions/wk). Oral S-1 was administered concomitantly in the IF-IMRT + S-1 group for 14 consecutive days, and a second cycle was started 7 d after drug withdrawal. After RT, 4 cycles of S-1 treatment were offered as the consolidation chemotherapy. The safety, short-term response, and survival were observed after the treatment.RESULTS: As of April 2022, these 34 patients had been followed up for 15.2-32.5 mo, with a median follow-up period of 24.5 mo. Complete efficacy indicators were obtained from all the patients. The objective response rate was 88.2% vs 76.5%, respectively, in the IF-IMRT + S-1 group and the RT alone group, where as the disease control rate was 100% vs 82.4%, respectively. The incidence of adverse events including grade 1-2 fatigue, granulocytopenia, thrombocytopenia, anemia, radiation esophagitis, radiation-induced skin injury, and radiation-induced lung injury was not significantly different between these two groups, so was the incidence of the grade 3 radiation esophagitis (0% vs 5.7%). The rate of progressive disease (PD) was 52.9% (n = 9) in the IF-IMRT + S-1 group and 64.7% (n = 11) in the RT alone group. The median progression-free survival (PFS) was 23.4 mo vs 16.3 mo, and the 2-year PFS rate was 42% vs 41.2%. The median overall survival (OS) was 27.0 mo vs 23.0 mo, and the 2-year OS rate was 58.8% vs 47.1%. Multivariate analysis showed that age was a significant prognostic factor (P = 0.0019); patients aged < 75 years had a significant survival advantage over patients aged ≥ 75 years. The locations of EC also affected the prognosis. In the IF-IMRT + S-1 group, the number of chemotherapy cycles was a significant prognostic factor (P = 0.0125), and the risk of PD was significantly lower in EC patients who had received 6 cycles of chemotherapy than those who had received 2-5 cycles of chemotherapy.CONCLUSION: Compared with IF-IMRT alone, IF-IMRT + S-1 shows the benefits of preventing PD and prolonging survival without increasing adverse reactions. Therefore, this concurrent radiochemotherapy deserves clinical application.

Late Course Accelerated Hyperfractionation Radiotherapy Combined with Chemotherapy for Elderly Patients with Esophageal Carcinoma

Long-Term Treatment Outcomes of the Elder Patients with Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma with Definitive Chemoradiotherapy or Radiotherapy.

Late Course Accelerated Hyperfractionation Radiotherapy for Elderly Patients with Esophageal Carcinoma

Clinical Study of Late-Course Three-Dimensional Conformal Radiotherapy for Esophageal Carcinoma

Concurent Chemotherapy Combined with Late Course Accelerated Hyperfractionated Radiotherapy for Advanced Esophageal Carcinoma

Comparison of involved-field intensity-modulated radiotherapy combined with S-1 vs radiotherapy alone for elderly patients with esophageal cancer

A Meta-analysis of survival of middle and late stage esophageal carcinoma treated with radiotherapy combined with traditional Chinese medicine

Meta-analysis of Late Course Accelerated Hyperfractionated Radiotherapy Combined with FP Chemotherapy for Esophageal Carcinoma

Toxic Reactions after Late Course Accelerated Hyperfractionated Radiotherapy Plus Concurrent Chemotherapy for Esophageal Carcinoma

Late Course Accelerated Hyperfractionation Radiotherapy for Esophageal Carcinoma

Randomized Study on Late Course Accelerated Hyperfractionation Radiotherapy Plus Cisplatin in the Treatment of Esophageal Carcinoma

Clinical Features, Outcomes and Treatment-Related Pneumonitis in Elderly Patients with Esophageal Carcinoma.

Benefit of chemotherapy based on platinum with definitive radiotherapy in older patients with locally advanced esophageal squamous cell carcinoma

Retrospective analysis on results of late course accelerated hyperfractionation radiotherapy and conventional fractionation radiotherapy plus brachytherapy for esophageal carcinoma

Safety Assessment for Radiotherapy Combined with Chemotherapy or Not in 63 Elderly Patients with Gastric Cancer

Conformal Radiotherapy for Esophageal Carcinoma in High-aged Patients

Prognosis of radiotherapy for esophageal cancer in elderly patients exceeding seventy-five years old

Conditional survival and annual hazard of death in elderly patients with esophageal cancer receiving definitive chemoradiotherapy

Radiotherapy for patients with esophageal cancer aged 80 years or older: A 16-year experience

The effect of surgery plus chemoradiotherapy on survival of elderly patients with stage II–III esophageal cancer: a SEER‐based demographic analysis

Efficacy and Safety of Concurrent Chemoradiotherapy Combined with Nimotuzumab in Elderly Patients with Esophageal Squamous Cell Carcinoma: A Prospective Real-world Pragmatic Study.